Drugs / MPHOSPH1-9-278
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00635336 | Feb 2007 | urinary bladder cancer | Iwate Medical University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00633204 | Feb 2008 → Nov 2011 | urinary bladder cancer | Iwate Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPHOSPH1-9-278 | “DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously.” NCT00633204 ↗1“DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks.” NCT00635336 ↗ |
| Route | Subcutaneous | “DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously.” NCT00633204 ↗ |
| Target | MPHOSPH1 | “epitope peptides derived from DEPDC1, DEPDC1-9-294, and MPHOSPH1, MPHOSPH1-9-278” NCT00633204 ↗ |